Vaccine development against Neisseria meningitidis

Microbial Biotechnology

Volumn 4, Issue 1, 2011, Pages 20-31

  Vogel, Ulrich ^a   Claus, Heike ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; SUBUNIT VACCINE;

BACTERIAL STRAIN; DRUG EFFICACY; DRUG SCREENING; HUMAN; MENINGOCOCCOSIS; MORBIDITY; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW;

ANIMALS; DRUG DESIGN; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS;

BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE; NEISSERIA MENINGITIDIS; STREPTOCOCCUS PNEUMONIAE;

EID: 77954155100     PISSN: 17517907     EISSN: 17517915     Source Type: Journal    
DOI: 10.1111/j.1751-7915.2010.00178.x     Document Type: Review

References (116)

1. Achtman, M., and Wagner, M. (2008) Microbial diversity and the genetic nature of microbial species. Nat Rev Microbiol 6: 431-440.
2. van Alphen, L., and van den Dobbelsteen, G. (2008) Meningococcal B vaccine development and evaluation of efficacy. Hum Vaccin 4: 158-161.
3. Ashton, F.E., Ryan, J.A., Michon, F., and Jennings, H.J. (1989) Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide. Microb Pathog 6: 455-458.
4. Auckland, C., Gray, S., Borrow, R., Andrews, N., Goldblatt, D., Ramsay, M., and Miller, E. (2006) Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 194: 1745-1752.
5. Balmer, P., Borrow, R., and Miller, E. (2002) Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 51: 717-722.
6. Bambini, S., Muzzi, A., Olcen, P., Rappuoli, R., Pizza, M., and Comanducci, M. (2009) Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27: 2794-2803.
7. Beernink, P.T., and Granoff, D.M. (2009) The modular architecture of meningococcal factor H-binding protein. Microbiology 155: 2873-2883.
8. Bentley, S.D., Vernikos, G.S., Snyder, L.A., Churcher, C., Arrowsmith, C., Chillingworth, T., etal. (2007) Meningococcal Genetic Variation Mechanisms Viewed through Comparative Analysis of Serogroup C Strain FAM18. PLoS Genet 3: e23.
9. Berry, D.S., Lynn, F., Lee, C.H., Frasch, C.E., and Bash, M.C. (2002) Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect Immun 70: 3707-3713.
10. Bhattacharjee, A.K., Jennings, H.J., Kenny, C.P., Martin, A., and Smith, I.C.P. (1975) Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem 250: 1926-1932.
11. Bhattacharjee, A.K., Jennings, H.J., Kenny, C.P., Martin, A., and Smith, I.C. (1976) Structural determination of the polysaccharide antigens of Neisseria meningitidis serogroups Y, W-135, and BO1. Can J Biochem 54: 1-8.
12. Bjune, G., Hoiby, E.A., Gronnesby, J.K., Arnesen, O., Fredriksen, J.H., Halstensen, A., etal. (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338: 1093-1096.
13. du-Bobie, J., Lupetti, P., Brunelli, B., Granoff, D., Norais, N., Ferrari, G., etal. (2004) GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence. Infect Immun 72: 1914-1919.
14. Boisier, P., Nicolas, P., Djibo, S., Taha, M.K., Jeanne, I., Mainassara, H.B., etal. (2007) Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 44: 657-663.
15. Borrow, R., and Miller, E. (2006) Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev Vaccines 5: 851-857.
16. Borrow, R., Andrews, N., Findlow, H., Waight, P., Southern, J., Crowley-Luke, A., etal. (2010) Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 17: 154-159.
17. Brehony, C., Wilson, D.J., and Maiden, M.C. (2009) Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 155: 4155-4169.
18. Bruge, J., Bouveret-Le, C.N., Danve, B., Rougon, G., and Schulz, D. (2004) Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 22: 1087-1096.
19. Buckee, C.O., Jolley, K.A., Recker, M., Penman, B., Kriz, P., Gupta, S., and Maiden, M.C. (2008) Role of selection in the emergence of lineages and the evolution of virulence in Neisseria meningitidis. Proc Natl Acad Sci USA 105: 15082-15087.
20. Bundle, D.R., Smith, I.C., and Jennings, H.J. (1974) Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance. Studies on the group-specific antigens of Neisseria meningitidis serogroups A and X. J Biol Chem 249: 2275-2281.
21. Cano, R., Larrauri, A., Mateo, S., Alcala, B., Salcedo, C., and Vazquez, J.A. (2004) Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill 9: 11-15.
22. Cantini, F., Veggi, D., Dragonetti, S., Savino, S., Scarselli, M., Romagnoli, G., etal. (2009) Solution structure of the factor H-binding protein, a survival factor and protective antigen of Neisseria meningitidis. J Biol Chem 284: 9022-9026.
23. Caugant, D.A., Froholm, L.O., Bovre, K., Holten, E., Frasch, C.E., Mocca, L.F., etal. (1986) Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci USA 83: 4927-4931.
24. Caugant, D.A., Tzanakaki, G., and Kriz, P. (2007) Lessons from meningococcal carriage studies. FEMS Microbiol Rev 31: 52-63.
25. Ciabattini, A., Giomarelli, B., Parigi, R., Chiavolini, D., Pettini, E., Arico, B., etal. (2008) Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA. Vaccine 26: 4244-4250.
26. Claus, H., Vogel, U., Mühlenhoff, M., Gerardy-Schahn, R., and Frosch, M. (1997) Molecular divergence of the sia locus in different serogroups of Neisseria meningitidis expressing polysialic acid capsules. Mol Gen Genet 257: 28-34.
27. Claus, H., Maiden, M.C., Maag, R., Frosch, M., and Vogel, U. (2002) Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology 148: 1813-1819.
28. Claus, H., Borrow, R., Achtman, M., Morelli, G., Kantelberg, C., Longworth, E., etal. (2004) Genetics of capsule O-acetylation in serogroup C, W-135 and Y meningococci. Mol Microbiol 51: 227-239.
29. Claus, H., Maiden, M.C., Wilson, D.J., McCarthy, N.D., Jolley, K.A., Urwin, R., etal. (2005) Genetic analysis of meningococci carried by children and young adults. J Infect Dis 191: 1263-1271.
30. Claus, H., Stummeyer, K., Batzilla, J., Mühlenhoff, M., and Vogel, U. (2009) Amino acid 310 determines the donor substrate specificity of serogroup W-135 and Y capsule polymerases of Neisseria meningitidis. Mol Microbiol 71: 960-971.
31. Coen, P.G., Cartwright, K., and Stuart, J. (2000) Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica. Int J Epidemiol 29: 180-188.
32. Comanducci, M., Bambini, S., Brunelli, B., du-Bobie, J., Arico, B., Capecchi, B., etal. (2002) NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195: 1445-1454.
33. Comanducci, M., Bambini, S., Caugant, D.A., Mora, M., Brunelli, B., Capecchi, B., etal. (2004) NadA diversity and carriage in Neisseria meningitidis. Infect Immun 72: 4217-4223.
34. Delgado, M., Yero, D., Niebla, O., Gonzalez, S., Climent, Y., Perez, Y., etal. (2007) Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate. Vaccine 25: 8420-8431.
35. Djibo, S., Nicolas, P., Alonso, J.M., Djibo, A., Couret, D., Riou, J.Y., and Chippaux, J.P. (2003) Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 8: 1118-1123.
36. Elias, J., and Vogel, U. (2007) IS1301 fingerprint analysis of Neisseria meningitidis strains belonging to the ET-15 clone. J Clin Microbiol 45: 159-167.
37. Elias, J., Harmsen, D., Claus, H., Hellenbrand, W., Frosch, M., and Vogel, U. (2006) Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerg Infect Dis 12: 1689-1695.
38. Feavers, I.M., Heath, A.B., Bygraves, J.A., and Maiden, M.C. (1992) Role of horizontal genetic exchange in the antigenic variation of the class 1 outer membrane protein of Neisseria meningitidis. Mol Microbiol 6: 489-495.
39. Feavers, I.M., and Pizza, M. (2009) Meningococcal protein antigens and vaccines. Vaccine 27 (Suppl. 2):B42-B50.
40. Findlow, H., Vogel, U., Mueller, J.E., Curry, A., Njanpop-Lafourcade, B.M., Claus, H., etal. (2007) Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso. J Infect Dis 195: 1071-1077.
41. Finney, M., Vaughan, T., Taylor, S., Hudson, M.J., Pratt, C., Wheeler, J.X., etal. (2008) Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccin 4: 23-30.
42. Fletcher, L.D., Bernfield, L., Barniak, V., Farley, J.E., Howell, A., Knauf, M., etal. (2004) Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72: 2088-2100.
43. Frasch, C.E., and Gotschlich, E.C. (1974) An outer membrane protein of Neisseria meningitidis group B responsible for serotype specificity. J Exp Med 140: 87-104.
44. Fusco, P.C., Michon, F.-R., Tai, J.Y., and Blake, M.S. (1997) Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis 175: 364-372.
45. Giuliani, M.M., du-Bobie, J., Comanducci, M., Arico, B., Savino, S., Santini, L., etal. (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103: 10834-10839.
46. Gold, R., Goldschneider, I., Lepow, M.L., Draper, T.F., and Randolph, M. (1978) Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis 137: 112-121.
47. Gorringe, A.R., Taylor, S., Brookes, C., Matheson, M., Finney, M., Kerr, M., etal. (2009) Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin Vaccine Immunol 16: 1113-1120.
48. Granoff, D.M., Bartoloni, A., Ricci, S., Gallo, E., Rosa, D., Ravenscroft, N., etal. (1998) Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 160: 5028-5036.
49. Grifantini, R., Sebastian, S., Frigimelica, E., Draghi, M., Bartolini, E., Muzzi, A., etal. (2003) Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci USA 100: 9542-9547.
50. Gudlavalleti, S.K., Datta, A.K., Tzeng, Y.L., Noble, C., Carlson, R.W., and Stephens, D.S. (2004) The Neisseria meningitidis serogroup A capsular polysaccharide O-3 and O-4 acetyltransferase. J Biol Chem 279: 42765-42773.
51. Harrison, O.B., Maiden, M.C., and Rokbi, B. (2008) Distribution of transferrin binding protein B gene (tbpB) variants among Neisseria species. BMC Microbiol 8: 66.
52. Hoang, L.M., Thomas, E., Tyler, S., Pollard, A.J., Stephens, G., Gustafson, L., etal. (2005) Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin Infect Dis 40: e38-e42.
53. Holst, J., Feiring, B., Naess, L.M., Norheim, G., Kristiansen, P., Hoiby, E.A., etal. (2005) The concept of 'tailor-made', protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 23: 2202-2205.
54. Hou, V.C., Koeberling, O., Welsch, J.A., and Granoff, D.M. (2005) Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 192: 580-590.
55. Howitz, M., Krause, T.G., Simonsen, J.B., Hoffmann, S., Frisch, M., Nielsen, N.M., etal. (2007) Lack of association between group B meningococcal disease and autoimmune disease. Clin Infect Dis 45: 1327-1334.
56. Hsu, C.A., Lin, W.R., Li, J.C., Liu, Y.L., Tseng, Y.T., Chang, C.M., etal. (2008) Immunoproteomic identification of the hypothetical protein NMB1468 as a novel lipoprotein ubiquitous in Neisseria meningitidis with vaccine potential. Proteomics 8: 2115-2125.
57. Jennings, H.J., Bhattacharjee, A.K., Bundle, D.R., Kenny, C.P., Martin, A., and Smith, I.C. (1977) Structures of the capsular polysaccharides of Neisseria meningitidis as determined by 13C-nuclear magnetic resonance spectroscopy. J Infect Dis 136(Suppl.):S78-S83.
58. Jennings, H.J., Gamian, A., and Ashton, F.E. (1987) N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J Exp Med 165: 1207-1211.
59. Kelly, C., Arnold, R., Galloway, Y., and O'Hallahan, J. (2007) A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 166: 817-823.
60. Keyserling, H., Papa, T., Koranyi, K., Ryall, R., Bassily, E., Bybel, M.J., etal. (2005) Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 159: 907-913.
61. Kristiansen, B.E., Lind, K.W., Mevold, K., Sorensen, B., Froholm, L.O., Bryn, K., etal. (1988) Meningococcal phenotypic and genotypic characteristics and human antibody levels. J Clin Microbiol 26: 1988-1992.
62. Kshirsagar, N., Mur, N., Thatte, U., Gogtay, N., Viviani, S., Preziosi, M.P., etal. (2007) Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 25 (Suppl. 1):A101-A107.
63. LaForce, F.M., Konde, K., Viviani, S., and Preziosi, M.P. (2007) The meningitis vaccine project. Vaccine 25 (Suppl. 1):A97-100.
64. van der Ley, P., Steeghs, L., Hamstra, H.J., ten Hove, J., Zomer, B., and van Alphen, L. (2001) Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 69: 5981-5990.
65. Li, Y., Sun, Y.H., Ison, C., Levine, M.M., and Tang, C.M. (2004) Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci. Infect Immun 72: 345-351.
66. Li, Y., Wooldridge, K.G., Javed, M.A., Tang, C.M., and Ala'Aldeen, D.A. (2009) Secreted proteins of Neisseria meningitidis protect mice against infection. Vaccine 27: 2320-2325.
67. Linz, B., Schenker, M., Zhu, P., and Achtman, M. (2000) Frequent interspecific genetic exchange between commensal neisseriae and Neisseria meningitidis. Mol Microbiol 36: 1049-1058.
68. Lo Passo, C., Romeo, A., Pernice, I., Donato, P., Midiri, A., Mancuso, G., etal. (2007) Peptide mimics of the group B meningococcal capsule induce bactericidal and protective antibodies after immunization. J Immunol 178: 4417-4423.
69. Lucidarme, J., Comanducci, M., Findlow, J., Gray, S.J., Kaczmarski, E.B., Guiver, M., etal. (2009) Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol 47: 3577-3585.
70. McNeil, L.K., Murphy, E., Zhao, X.J., Guttmann, S., Harris, S., Scott, A., etal. (2009) Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 27: 3417-3421.
71. Madico, G., Welsch, J.A., Lewis, L.A., McNaughton, A., Perlman, D.H., Costello, C.E., etal. (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177: 501-510.
72. Maiden, M.C., and Spratt, B.G. (1999) Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 354: 615-616.
73. Maiden, M.C., and Stuart, J.M. (2002) Carriage of serogroup C meningococci 1year after meningococcal C conjugate polysaccharide vaccination. Lancet 359: 1829-1831.
74. Maiden, M.C., Ibarz-Pavon, A.B., Urwin, R., Gray, S.J., Andrews, N.J., Clarke, S.C., etal. (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197: 737-743.
75. Mascioni, A., Bentley, B.E., Camarda, R., Dilts, D.A., Fink, P., Gusarova, V., etal. (2009) Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086. J Biol Chem 284: 8738-8746.
76. Michon, F., Huang, C.H., Farley, E.K., Hronowski, L., Di, J., and Fusco, P.C. (2000) Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev Biol (Basel) 103: 151-160.
77. Moe, G.R., Bhandari, T.S., and Flitter, B.A. (2009) Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against neisseria meningitidis groups B and C. J Immunol 182: 6610-6617.
78. de Moraes, J.C., Perkins, B.A., Camargo, M.C., Hidalgo, N.T., Barbosa, H.A., Sacchi, C.T., etal. (1992) Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340: 1074-1078.
79. Murphy, E., Andrew, L., Lee, K.L., Dilts, D.A., Nunez, L., Fink, P.S., etal. (2009) Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200: 279-289.
80. Oliver, K.J., Reddin, K.M., Bracegirdle, P., Hudson, M.J., Borrow, R., Feavers, I.M., etal. (2002) Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 70: 3621-3626.
81. Oster, P., Lennon, D., O'Hallahan, J., Mulholland, K., Reid, S., and Martin, D. (2005) MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23: 2191-2196.
82. Ostergaard, L., Lebacq, E., Poolman, J., Maechler, G., and Boutriau, D. (2009) Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25years. Vaccine 27: 161-168.
83. Park, I., Choi, I.H., Kim, S.J., and Shin, J.S. (2004) Peptide mimotopes of Neisseria meningitidis group B capsular polysaccharide. Yonsei Med J 45: 755-758.
84. Parkhill, J., Achtman, M., James, K.D., Bentley, S.D., Churcher, C., Klee, S.R., etal. (2000) Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404: 502-506.
85. Peng, J., Yang, L., Yang, F., Yang, J., Yan, Y., Nie, H., etal. (2008) Characterization of ST-4821 complex, a unique Neisseria meningitidis clone. Genomics 91: 78-87.
86. Pillai, S., Howell, A., Alexander, K., Bentley, B.E., Jiang, H.Q., Ambrose, K., etal. (2005) Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23: 2206-2209.
87. Pizza, M., Scarlato, V., Masignani, V., Giuliani, M.-M., Arico, B., Comanducci, M., etal. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287: 1816-1820.
88. Pollabauer, E.M., Petermann, R., and Ehrlich, H.J. (2005) Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology. Hum Vaccin 1: 131-139.
89. Ramsay, M.E., Andrews, N.J., Trotter, C.L., Kaczmarski, E.B., and Miller, E. (2003) Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326: 365-366.
90. Richmond, P., Borrow, R., Goldblatt, D., Findlow, J., Martin, S., Morris, R., etal. (2001) Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 183: 160-163.
91. Rinaudo, C.D., Telford, J.L., Rappuoli, R., and Seib, K.L. (2009) Vaccinology in the genome era. J Clin Invest 119: 2515-2525.
92. Rouaud, P., Perrocheau, A., Taha, M.K., Sesboue, C., Forgues, A.M., Parent du Châtelet, I., and Levy-Bruhl, D. (2006) Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005. Euro Surveill 11: 178-181.
93. Russell, J.E., Jolley, K.A., Feavers, I.M., Maiden, M.C., and Suker, J. (2004) PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 10: 674-678.
94. Schneider, M.C., Prosser, B.E., Caesar, J.J., Kugelberg, E., Li, S., Zhang, Q., etal. (2009) Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458: 890-893.
95. Schoen, C., Blom, J., Claus, H., Schramm-Gluck, A., Brandt, P., Muller, T., etal. (2008) Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis. Proc Natl Acad Sci USA 105: 3473-3478.
96. Shin, J.S., Lin, J.S., Anderson, P.W., Insel, R.A., and Nahm, M.H. (2001) Monoclonal antibodies specific for Neisseria meningitidis group B polysaccharide and their peptide mimotopes. Infect Immun 69: 3335-3342.
97. Sierra, G.V., Campa, H.C., Varcacel, N.M., Garcia, I.L., Izquierdo, P.L., Sotolongo, P.F., etal. (1991) Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14: 195-207.
98. Sjolinder, H., Eriksson, J., Maudsdotter, L., Aro, H., and Jonsson, A.B. (2008) Meningococcal outer membrane protein NhhA is essential for colonization and disease by preventing phagocytosis and complement attack. Infect Immun 76: 5412-5420.
99. Snape, M.D., Kelly, D.F., Green, B., Moxon, E.R., Borrow, R., and Pollard, A.J. (2005) Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 24: 128-131.
100. Snape, M.D., Kelly, D.F., Salt, P., Green, S., Snowden, C., Diggle, L., etal. (2006) Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3years after immunization. Clin Infect Dis 43: 1387-1394.
101. Snape, M.D., Perrett, K.P., Ford, K.J., John, T.M., Pace, D., Yu, L.M., etal. (2008) Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299: 173-184.
102. Stephens, D.S. (2007) Conquering the meningococcus. FEMS Microbiol Rev 31: 3-14.
103. Stoddard, M.B., Pinto, V., Keiser, P.B., and Zollinger, W. (2010) Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. Clin Vaccine Immunol 17: 98-107.
104. Tettelin, H., Saunders, N.J., Heidelberg, J., Jeffries, A.C., Nelson, K.E., Eisen, J.A., etal. (2000) Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287: 1809-1815.
105. Thompson, E.A., Feavers, I.M., and Maiden, M.C. (2003) Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 149: 1849-1858.
106. Toikka, J., Aalto, J., Hayrinen, J., Pelliniemi, L.J., and Finne, J. (1998) The polysialic acid units of the neural cell adhesion molecule N-CAM form filament bundle networks. J Biol Chem 273: 28557-28559.
107. Trotter, C.L., Andrews, N.J., Kaczmarski, E.B., Miller, E., and Ramsay, M.E. (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4years after introduction. Lancet 364: 365-367.
108. Trotter, C.L., Edmunds, W.J., Ramsay, M.E., and Miller, E. (2006) Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales. Hum Vaccin 2: 68-73.
109. Trotter, C.L., McVernon, J., Ramsay, M.E., Whitney, C.G., Mulholland, E.K., Goldblatt, D., etal. (2008) Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 26: 4434-4445.
110. van Ulsen, P., and Tommassen, J. (2006) Protein secretion and secreted proteins in pathogenic Neisseriaceae. FEMS Microbiol Rev 30: 292-319.
111. Urwin, R., Russell, J.E., Thompson, E.A., Holmes, E.C., Feavers, I.M., and Maiden, M.C. (2004) Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 72: 5955-5962.
112. Vogel, U., Claus, H., and Frosch, M. (2000) Rapid serogroup switching in Neisseria meningitidis. N Engl J Med 342: 219-220.
113. Vogel, U., Claus, H., von Muller, L., Bunjes, D., Elias, J., and Frosch, M. (2004) Bacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl). J Clin Microbiol 42: 2898-2901.
114. West, D., Reddin, K., Matheson, M., Heath, R., Funnell, S., Hudson, M., etal. (2001) Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun 69: 1561-1567.
115. Weynants, V.E., Feron, C.M., Goraj, K.K., Bos, M.P., Denoel, P.A., Verlant, V.G., etal. (2007) Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 75: 5434-5442.
116. Weynants, V., Denoel, P., Devos, N., Janssens, D., Feron, C., Goraj, K., etal. (2009) Genetically modified L3, 7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect Immun 77: 2084-2093.